NASDAQ:TERN

Terns Pharmaceuticals Competitors

$17.74
-1.19 (-6.29 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.00
Now: $17.74
$19.00
50-Day Range
$17.13
MA: $21.92
$27.25
52-Week Range
$14.83
Now: $17.74
$28.36
Volume75,436 shs
Average Volume205,242 shs
Market Capitalization$445.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Terns Pharmaceuticals (NASDAQ:TERN) Vs. IBRX, BCAB, IMCR, EWTX, KNTE, and CGEM

Should you be buying TERN stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Terns Pharmaceuticals, including ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), Cricut (EWTX), Kinnate Biopharma (KNTE), and Cullinan Oncology (CGEM).

ImmunityBio (NASDAQ:IBRX) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Valuation and Earnings

This table compares ImmunityBio and Terns Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares ImmunityBio and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for ImmunityBio and Terns Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Terns Pharmaceuticals00303.00

ImmunityBio presently has a consensus target price of $25.00, suggesting a potential upside of 55.38%. Terns Pharmaceuticals has a consensus target price of $30.50, suggesting a potential upside of 71.93%. Given Terns Pharmaceuticals' higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than ImmunityBio.

Summary

Terns Pharmaceuticals beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Valuation and Earnings

This table compares BioAtla and Terns Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares BioAtla and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for BioAtla and Terns Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Terns Pharmaceuticals00303.00

BioAtla presently has a consensus target price of $58.00, suggesting a potential upside of 20.26%. Terns Pharmaceuticals has a consensus target price of $30.50, suggesting a potential upside of 71.93%. Given Terns Pharmaceuticals' higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than BioAtla.

Terns Pharmaceuticals (NASDAQ:TERN) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Terns Pharmaceuticals and Immunocore's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Profitability

This table compares Terns Pharmaceuticals and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Terns PharmaceuticalsN/AN/AN/A
ImmunocoreN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Terns Pharmaceuticals and Immunocore, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Terns Pharmaceuticals00303.00
Immunocore01202.67

Terns Pharmaceuticals presently has a consensus price target of $30.50, suggesting a potential upside of 71.93%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 68.63%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Terns Pharmaceuticals is more favorable than Immunocore.

Summary

Terns Pharmaceuticals beats Immunocore on 3 of the 3 factors compared between the two stocks.

Terns Pharmaceuticals (NASDAQ:TERN) and Cricut (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Terns Pharmaceuticals and Cricut's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/AN/AN/AN/A
CricutN/AN/AN/AN/AN/A

Profitability

This table compares Terns Pharmaceuticals and Cricut's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Terns PharmaceuticalsN/AN/AN/A
CricutN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Terns Pharmaceuticals and Cricut, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Terns Pharmaceuticals00303.00
Cricut0000N/A

Terns Pharmaceuticals presently has a consensus price target of $30.50, suggesting a potential upside of 71.93%. Given Terns Pharmaceuticals' higher possible upside, equities analysts clearly believe Terns Pharmaceuticals is more favorable than Cricut.

Summary

Terns Pharmaceuticals beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kinnate Biopharma and Terns Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kinnate Biopharma00403.00
Terns Pharmaceuticals00303.00

Kinnate Biopharma presently has a consensus price target of $52.00, suggesting a potential upside of 73.39%. Terns Pharmaceuticals has a consensus price target of $30.50, suggesting a potential upside of 71.93%. Given Kinnate Biopharma's higher possible upside, equities research analysts clearly believe Kinnate Biopharma is more favorable than Terns Pharmaceuticals.

Valuation and Earnings

This table compares Kinnate Biopharma and Terns Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kinnate BiopharmaN/AN/AN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Kinnate Biopharma and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kinnate BiopharmaN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/A

Summary

Kinnate Biopharma beats Terns Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Profitability

This table compares Cullinan Oncology and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cullinan Oncology and Terns Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology01302.75
Terns Pharmaceuticals00303.00

Cullinan Oncology presently has a consensus price target of $48.25, suggesting a potential upside of 61.53%. Terns Pharmaceuticals has a consensus price target of $30.50, suggesting a potential upside of 71.93%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Cullinan Oncology.

Valuation and Earnings

This table compares Cullinan Oncology and Terns Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Terns Pharmaceuticals beats Cullinan Oncology on 2 of the 2 factors compared between the two stocks.


Terns Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IBRX
ImmunityBio
1.7$16.09-4.8%$1.76 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.5$48.23-1.8%$1.62 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$32.22-10.1%$1.39 billionN/A0.00News Coverage
Gap Down
EWTX
Cricut
0.3$28.61-3.3%$1.36 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$29.99-5.2%$1.30 billionN/A0.00Increase in Short Interest
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$29.87-8.1%$1.30 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$35.15-8.3%$1.23 billionN/A0.00
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.13-0.3%$1.19 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$26.63-9.4%$1.18 billionN/A0.00Increase in Short Interest
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.05-0.3%$951.68 millionN/A0.00Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.01-2.3%$923.52 millionN/A0.00News Coverage
FDMT
4D Molecular Therapeutics
1.3$34.42-9.5%$918.81 millionN/A0.00Increase in Short Interest
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.89-2.8%$910.67 millionN/A0.00Gap Down
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$24.27-11.3%$851.85 millionN/A0.00Increase in Short Interest
PHAR
Pharming Group
0.0$12.80-3.6%$816.72 millionN/A0.00Decrease in Short Interest
Gap Up
FNCH
Finch Therapeutics Group
0.3$17.10-0.5%$806.18 millionN/A0.00News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$21.84-6.2%$793.40 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.35-0.6%$554.34 millionN/A0.00News Coverage
SGTX
Sigilon Therapeutics
1.4$17.43-1.9%$548.92 millionN/A0.00Increase in Short Interest
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$12.59-5.0%$541.36 millionN/A0.00Analyst Revision
News Coverage
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.50-2.6%$443.53 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$14.81-4.5%$436.66 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.74-4.7%$426.49 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.15-2.2%$407.20 millionN/A0.00
PRTG
Portage Biotech
0.0$28.97-0.9%$350.05 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.60-4.1%$306.31 millionN/A-2.98
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.99-1.1%$296.84 millionN/A-2.76
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.53-0.1%$262.22 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$12.31-0.2%$235.36 millionN/A0.00Increase in Short Interest
Gap Down
LBPH
Longboard Pharmaceuticals
1.9$12.99-23.2%$219.75 millionN/A0.00
Annovis Bio logo
ANVS
Annovis Bio
0.0$25.07-5.9%$174.16 millionN/A0.00
GANX
Gain Therapeutics
1.0$14.00-0.1%$158.63 millionN/A0.00Analyst Report
News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$18.62-2.4%$152.78 millionN/A0.00
LGVN
Longeveron
0.3$6.92-1.6%$129.45 millionN/A0.00News Coverage
EVAX
Evaxion Biotech A/S
1.7$6.40-4.8%$122.87 millionN/A0.00Gap Down
UPC
Universe Pharmaceuticals
0.0$4.22-10.0%$91.79 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.73-0.4%$61.47 millionN/A0.00Decrease in Short Interest
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.56-1.1%$55.88 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.99-3.0%$49.90 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.72-4.0%$43.82 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.44-5.0%$30.24 millionN/A0.00High Trading Volume
VRPX
Virpax Pharmaceuticals
0.3$4.78-1.7%$23.64 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$39.73-15.5%$18.44 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.71-8.4%$15.16 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.92-32.9%$3.03 millionN/A0.00High Trading Volume
News Coverage
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.05-5.6%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.72-8.1%$0.00N/A0.00Gap Up
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00Increase in Short Interest
RPHM
Reneo Pharmaceuticals
0.0$12.75-8.9%$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.